Drug-Drug Interactions and Acute Kidney Injury: Caveat Prescriptor

Mendu, Mallika L.; Waikar, Sushrut S.

doi:10.1053/j.ajkd.2014.04.015

Cited by 2 publications

(1 citation statement)

References 23 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“… 16 , 17 Therefore, physicians who prescribe medications could receive warnings from electronic supportive system and avoid the potential risk of drug interactions. 18 …”

Section: Discussionmentioning

confidence: 99%

Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers

et al. 2016

View full text Add to dashboard Cite

Some statins (simvastatin, lovastatin, and atorvastatin) are metabolized by cytochrome P450s 3A4 (CYP3A4). Inhibitors of CYP3A4 including some calcium channel blockers (CCBs) might increase statin blood concentration, owing to drug–drug interactions. Risk of adverse events such as acute kidney injury might occur following the coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4.This was a population-based cohort study. The study analyzed data of patients treated between 1997 and 2011, retrieved from Taiwan's National Health Insurance database. We enrolled 32,801 patients who received coprescription of statins and CCBs that inhibit CYP3A4 (amlodipine, diltiazem, felodipine nicardipine, nifedipine, and verapamil). These patients were divided into 2 groups, according to whether they had received CYP3A4-metabolized statins (lovastatin, simvastatin, and atorvastatin) or non-CYP3A4-metabolized statins (fluvastatin, rosuvastatin, and pitavastatin). These 2 groups were 1:1 matched by age, gender, and Carlson comorbidity index. All outcomes were assessed within 90 days following drug coprescription.In this study, 5857 patients received coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4. There were no differences in comorbidity or use of antihypertensive drugs between patients who received CYP3A4-metabolized statins and those who received non-CYP3A4-metabolized statins. Patients who received CYP3A4-metabolized statins had significantly higher risk of acute kidney injury (adjusted odds ratio [OR] = 2.12; 95% CI = 1.35–3.35), hyperkalemia (adjusted OR = 2.94; 95% CI = 1.36–6.35), acute myocardial infarction (adjusted OR = 1.55; 95% CI = 1.16–2.07), and acute ischemic stroke (adjusted OR = 1.35; 95% CI = 1.08–1.68) than those who received non-CYP3A4-metabolized statins.This nationwide cohort study demonstrated the increased risk of adverse events following the coprescription of CYP3A4-metabolized statins and CCBs that inhibit CYP3A4. Therefore, it is important to take into account the potential adverse events while coprescribing CYP3A4-metabolized statins and CCBs that inhibit CYP3A4.

show abstract

“… 16 , 17 Therefore, physicians who prescribe medications could receive warnings from electronic supportive system and avoid the potential risk of drug interactions. 18 …”

Section: Discussionmentioning

confidence: 99%

Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers

et al. 2016

View full text Add to dashboard Cite

show abstract

Acute kidney injury

Lang

Zuber²,

Davis³

2016

Journal of the American Academy of Physician Assistants

View full text Add to dashboard Cite

Acute kidney injury (AKI) complicates up to 20% of all hospital admissions. Responding to the increase in admissions, complications, mortality, morbidity, and cost of AKI, Kidney Disease: Improving Global Outcomes convened an expert panel to study the issue, review the literature, and publish guidelines to evaluate and treat patients with AKI in the acute setting. This article reviews those guidelines.

show abstract

Drug-Drug Interactions and Acute Kidney Injury: Caveat Prescriptor

Cited by 2 publications

References 23 publications

Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers

Risks of Adverse Events Following Coprescription of Statins and Calcium Channel Blockers

Acute kidney injury

Contact Info

Product

Resources

About